Hikma reports strong H1 performance, continues to expand portfolio

Hikma reports strong H1 performance, continues to expand portfolio
The headquarters of Hikma Pharmaceuticals. (Photo: Twitter)
AMMANHikma Pharmaceuticals, a multinational pharmaceutical company, reported its interim results on Thursday, which showed a strong performance in H1 of 2023.اضافة اعلان

According to a press statement, the group said that revenue went up by 18 percent with strong growth in all three business segments, reaching $1.427 billion, compared to the $1.213 billion recorded in H1 of 2022, Jordan News Agency, Petra reported.

Said Darwazah, Executive Chairman and Chief Executive Officer of Hikma, said: "Our strong first half performance reflects growth across all three of Hikma’s businesses and geographies. Across our global operations we have continued to strengthen our businesses and processes, including adding to, and enhancing our manufacturing capabilities."

"Our investments in research and development have yielded several new product launches and pipeline expansion, broadening our differentiated product portfolio. We continue to win important new contracts and expand in new markets, all of which are enabling Hikma to make more medicines accessible to the healthcare providers and patients who need them most," he pointed out.

Read more National news
Jordan News